메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'

- First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., the world's first recombinant anthrax vaccine. The product, jointly developed by the Korea Disease Control and Prevention Agency (KDCA) and GC Biopharma, was granted regulatory approval in April as Korea's 39th locally developed new drug. The initial su
- 김갑성 기자
- 2025-12-08 14:36
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 8, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology (ASH) Annual Meeting. The poster was titled "A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma." The publ
- 김갑성 기자
- 2025-12-08 10:08
Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting

NANJING, China, Dec. 8, 2025 -- From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) delivered an oral presentation on the opening day of the conference featuring the Phase I/II clinical results of LBL-034, a GPRC5D/CD3 bispecific antibody with a unique 2:1 structure and conditional activation, independently developed using the proprietary LeadsBody platform, for the treatment of relapsed/refractor
- 김갑성 기자
- 2025-12-08 10:00
IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH

SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 8, 2025 -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune diseases, announced the oral presentation of updated clinical data for its independently developed, fully human BCMA-targeted CAR-T cell therapy product, Equecabtagene Autoleucel (Eque-cel), for the treatment of transplant-ineligible patients with high-risk newly diagnosed multiple my
- 김갑성 기자
- 2025-12-08 09:57
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced the initial data of the first-in-human trial of IBI3003, a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3 for the treatment of relapsed or refractory multiple myeloma (R/R MM)
- 김갑성 기자
- 2025-12-08 09:02
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Median overall survival not yet reached and is projected to exceed four years, which would surpass osimertinib monotherapy by more than one year. -- Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed amivantamab plus lazertinib led to a clinically meanin
- 김갑성 기자
- 2025-12-08 09:00
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

TOKYO, Dec. 8, 2025 -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately JPY 70 million (USD 460,0001) for the development of a prototype detection test for mpox (formerly known as monkeypox2). Mpox is a viral infectious disease that has been spreading in the Democratic Republic of the Congo (DRC) and across sub-Saharan Africa. According to a situation report by the World Health Organization (WHO), more than 170,000 cases of mpox were confirmed in 141 countries between January 2022 and October 20253. WHO also reported that surveillance d
- 김갑성 기자
- 2025-12-08 09:00
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 8, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology5 achieved PR or better. Six patients (ASH) Annual Meeting. The poster was titled "A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refra
- 김갑성 기자
- 2025-12-08 08:15
RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 8, 2025 -- AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare professionals in identifying acute inpatient deterioration using AI-enabled machine learning models. Compared to the current standard of care, 1Bio™AI-Acute delivers significantly higher precision in acute deterioration notifications, resulting in fewer false alerts and more efficient clinical support. The 1Bio™AI-Acute system use
- 김갑성 기자
- 2025-12-08 08:00
AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 8, 2025 -- ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a USD 45 million funding round led by Granite Asia. Founded in 2022, ChemLex develops AI technologies that radically accelerate chemical discovery for the pharmaceutical industry, significantly reducing time-to-market. In just three and a half years, it has grown to support more than 70 customers worldwide, including six of the world's top ten pharmaceutical companies. This surge refl
- 김갑성 기자
- 2025-12-08 08:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-12-19_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 19일 15시 20분